Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
DuPont Backs FY09 EPS View, Guides FY10 - Update
11/3/2009 2:11 PM  ET

RELATED NEWS
DuPont Board Elects CEO Ellen Kullman Chair - Quick Facts
DuPont Enters Into Royalty-bearing License Agreement With Makhteshim Agan Of North America - Quick Facts
DuPont Q3 Profit Rises; Revises FY09 EPS Outlook - Quick Facts 2
DuPont Q3 Profit Rises - Quick Facts 1
Ahead Of DuPont's Q3 Results
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Tuesday, science and technology company EI DuPont de Nemours & Co. (DD: News ), reaffirmed its earnings per share view for the full year 2009 and issued its earnings guidance for the full year 2010.

DuPont reaffirmed its full year 2009 non-GAAP earnings outlook of $1.95 to $2.05 per share, which excludes significant items estimated at $0.15 per share. On a GAAP basis, the company expects earnings in the range of $1.80 to $1.90 per share.

DuPont said that for full year 2010 it expects earnings to be in the range of $2.10 to $2.40 per share.

Chief Executive Officer Ellen Kullman commenting on the the company's strategy said, "Our focus is on delivering superior growth for our shareholders through customer-driven and science-based solutions, carefully prioritized investments, industry-leading productivity, and strict accountability."

The company expects to generate about 10% top-line compound annual growth for the 2009-2012 period. EI DuPont also plans to capture $1 billion in fixed cost productivity and $1 billion in working capital productivity gains during the 2010-2012 time frame.

The company in its investors meeting brief said its business segment contributions to the growth between 2009-2012 expects Agriculture & Nutrition to generate more than $2 billion in top-line growth through 2012.
Electronics & Communications segment is expected to improve its margins and deliver top-line growth, while safety & production segment is expected to generate 12-16% annual revenue growth.

The company aims to restore pre-tax operating margins to low double digits by 2012, delivering $300 million in fixed and variable cost productivity. EI DuPont's performance materials segment would focus on earnings growth and cash generation.

Further, EI DuPont expects its performance chemicals segment to deliver top-quartile performance among peers.

DD is currently trading at $32.63, up $0.36 or 1.12%, on the NYSE.

To receive FREE breaking news email alerts for DuPont and others in your portfolio


by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

127  Indian Appointed To Key IMF Post
126  FDA Approves Bristol-Myers' Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder - Update
125  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
124  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
123  CF Nominees Enter Terra's Board - Update
122  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
121  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
120  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
119  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
118  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
117  Covidien's Pain Drug NDA Review Extended By FDA - Update
116  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
115  Cloud Peak Energy Prices IPO At $15/shr - Update
114  Met-Pro Q3 Profit Plunges - Update
113  Boston Scientific Receives FDA's 510 (k)Clearance For WallFlex Fully Covered Esophageal Stent - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS